Insmed continues to work to delivery therapeutics to the lung for the treatment of nontuberculous mycobacterial lung infections (NTM).  Although the company has been recently punished by the investor community over results that failed to meet expectations, work continues on this promising therapeutic.  Arikayce, or inhaled liposomal amikacin,  is now being positioned for breakthrough discovery status.  Once again, we see the promise of therapeutic nanomaterials coming closing to mainstream application.